Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: J Am Acad Child Adolesc Psychiatry. 2020 Oct 15;60(7):856–864.e1. doi: 10.1016/j.jaac.2020.09.021

Figure 1: Attention-Deficit/Hyperactivity Disorder (ADHD) Symptom Scores by Study Phase.

Figure 1:

Note: Blinded treatment was discontinued between week 4 and 5 (indicated by dotted line). Sham crossover treatment began week 5. Black and blue arrows indicate pre- and post-treatment measurements for the Active Trial and Sham Crossover groups, respectively. BOCF=baseline observation carried forward; RS = rating scale.